Engineering hybrid nanoparticles for targeted codelivery of triptolide and CYP3A4 -siRNA against pulmonary metastatic melanoma
Science Advances · 25.07.2025 · 11 (30)
DOI: 10.1126/sciadv.adv6990 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 25.07.2025. Verfasst von Yongwei Gu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032,…. Hauptthemen laut MEDLINE: Phenanthrenes, Diterpenes, Lung Neoplasms, Cytochrome P-450 CYP3A. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Pulmonary metastatic melanoma (PMM) is an aggressive malignancy with limited response and rapid resistance to clinical chemotherapy, radiotherapy, immunotherapy, and biological therapies. Here, we developed a targeted biomimetic drug delivery system, TP-siRC@tHyNPs, by fusing exosomes derived from engineered cells overexpressing DR5 single-chain variable fragments (DR5-Exo) with liposomes coencapsulating triptolide (TP) and CYP3A4-siRNA (TP-siRC@Lip). DR5-Exo facilitated the targeted delivery of drug to tumor cells through DR5 receptor recognition and simultaneously activated apoptotic pathways. Moreover, CYP3A4-siRNA effectively prolonged the half-life of TP, thereby enhancing its antiproliferative and pro-apoptotic effects. Mechanistic studies revealed that TP-siRC@tHyNPs induced immunogenic cell death, reprogrammed macrophage polarization, arrested cell cycle progression, and triggered apoptotic pathways. In vivo experiments demonstrated that TP-siRC@tHyNPs specifically accumulated in lung tissue, notably inhibiting the growth of PMM while exhibiting negligible toxicity in tumor-bearing mice. Overall, this study provides a promising strategy for targeting PMM treatment, improving therapeutic efficacy while reducing off-target toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
- College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China.
- School of Pharmacy, Faculty of Medicine, Macau University of Science and Technology, Macau SAR, China.
- Shanghai Wei Er Lab, Shanghai 201707, China.
ORCID-Profile: Yongwei Gu, Aixue Li, Mengyuan He, Fu Qi, Xiaomeng Tang, Xin Wu, Jiyong Liu
Zitieren
APA
Gu, Y., Li, A., Zeng, Y., He, M., Qi, F., Liu, R., Cai, H., Li, D., Tang, X., Fu, Z., Wu, X., & Liu, J. (2025). Engineering hybrid nanoparticles for targeted codelivery of triptolide and CYP3A4 -siRNA against pulmonary metastatic melanoma. Science Advances, 11(30). https://doi.org/10.1126/sciadv.adv6990
Vancouver
Gu Y, Li A, Zeng Y, He M, Qi F, Liu R, et al. Engineering hybrid nanoparticles for targeted codelivery of triptolide and CYP3A4 -siRNA against pulmonary metastatic melanoma. Science Advances. 2025;11(30). doi:10.1126/sciadv.adv6990
BibTeX
@article{Gu2025,
author = {Gu, Yongwei and Li, Aixue and Zeng, Yuanye and He, Mengyuan and Qi, Fu and Liu, Rongmei and Cai, Huanhuan and Li, Dan and Tang, Xiaomeng and Fu, Zhiqin and Wu, Xin and Liu, Jiyong},
title = {Engineering hybrid nanoparticles for targeted codelivery of triptolide and CYP3A4 -siRNA against pulmonary metastatic melanoma},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {30},
doi = {10.1126/sciadv.adv6990}
}
EUVIMED